A wide range of pathological conditions is associated with detrimental immune responses to environmental antigens, autoantigens, transplanted cells or organs, and protein therapeutics. In the past, and true even to this day, generalized immunosuppression was/is the only successful intervention for some of these conditions. Targeted biologics such as monoclonal antibodies and other therapeutic agents have revolutionized the treatment of immune-mediated conditions through complementary pathways including interrupting effector mechanisms, restraining innate immune activation, and boosting regulation. Targeting these complementary pathways is key to the establishment or restoration of immune tolerance, resulting in prolonged or permanent modulation of pathological immune responses leading to significant clinical benefit while preserving protective immunity.
Despite remarkable advances, there is clear unmet medical need in terms of improving efficacy, increasing specificity, and reducing the toxicity of current options for treating immune-mediated pathologic conditions. This Research Topic focuses on cutting-edge therapeutic strategies in development for immune tolerance and regulation, some of which are likely to add to and complement the existing armamentarium of agents that target pathological immune responses. An additional area of focus is the potential for improvement in clinical outcomes by combining therapies that address pathogenic mechanisms from different strategic standpoints. The underlying immunological mechanisms for these innovative approaches and combinations will also be explored.
In this Research Topic we welcome the submission of Reviews, Mini Reviews, Opinion articles, and Original Research articles that focus on the exploration of new strategies for addressing tolerance induction in immune-mediated diseases, including but not limited to:
• Bioengineered regulatory or antigen directed cellular therapies
• Tolerizing peptide therapeutics
• Cytokine muteins
• Bispecific antibodies
• Antibody-drug conjugates and immunotoxins
• Chemokines
• Microbiome-based interventions
• Genetic approaches to tissue-specific expression in transplantation
• Novel lentiviral approaches for gene therapy
We welcome, in such articles, exploration of underlying immunological mechanisms and consideration of how these novel therapeutic approaches may be combined with complementary therapeutic approaches that may enhance their capacity to induce immune tolerance in pathologic settings.
Topic editor, Dr. Amy Rosenberg is employed by EpiVax, Inc. The other Topic Editor declares no competing interests in relation to the Topic focus
A wide range of pathological conditions is associated with detrimental immune responses to environmental antigens, autoantigens, transplanted cells or organs, and protein therapeutics. In the past, and true even to this day, generalized immunosuppression was/is the only successful intervention for some of these conditions. Targeted biologics such as monoclonal antibodies and other therapeutic agents have revolutionized the treatment of immune-mediated conditions through complementary pathways including interrupting effector mechanisms, restraining innate immune activation, and boosting regulation. Targeting these complementary pathways is key to the establishment or restoration of immune tolerance, resulting in prolonged or permanent modulation of pathological immune responses leading to significant clinical benefit while preserving protective immunity.
Despite remarkable advances, there is clear unmet medical need in terms of improving efficacy, increasing specificity, and reducing the toxicity of current options for treating immune-mediated pathologic conditions. This Research Topic focuses on cutting-edge therapeutic strategies in development for immune tolerance and regulation, some of which are likely to add to and complement the existing armamentarium of agents that target pathological immune responses. An additional area of focus is the potential for improvement in clinical outcomes by combining therapies that address pathogenic mechanisms from different strategic standpoints. The underlying immunological mechanisms for these innovative approaches and combinations will also be explored.
In this Research Topic we welcome the submission of Reviews, Mini Reviews, Opinion articles, and Original Research articles that focus on the exploration of new strategies for addressing tolerance induction in immune-mediated diseases, including but not limited to:
• Bioengineered regulatory or antigen directed cellular therapies
• Tolerizing peptide therapeutics
• Cytokine muteins
• Bispecific antibodies
• Antibody-drug conjugates and immunotoxins
• Chemokines
• Microbiome-based interventions
• Genetic approaches to tissue-specific expression in transplantation
• Novel lentiviral approaches for gene therapy
We welcome, in such articles, exploration of underlying immunological mechanisms and consideration of how these novel therapeutic approaches may be combined with complementary therapeutic approaches that may enhance their capacity to induce immune tolerance in pathologic settings.
Topic editor, Dr. Amy Rosenberg is employed by EpiVax, Inc. The other Topic Editor declares no competing interests in relation to the Topic focus
